<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03775200</url>
  </required_header>
  <id_info>
    <org_study_id>COMP001</org_study_id>
    <nct_id>NCT03775200</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression</brief_title>
  <acronym>P-TRD</acronym>
  <official_title>The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>COMPASS Pathways</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>COMPASS Pathways</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a
      dose-ranging study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>MADRS is a clinician-rated scale measuring depression severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of 60; higher scores denote greater severity. Response = &gt;50% decrease and Remission =&lt; 10 actual score.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Psilocybin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose Psilocybin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose Psilocybin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>Dose-ranging</description>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Medium dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Upper age limit of 54 years at Screening is applicable only to USA sites

        Inclusion Criteria:

          -  Diagnosis of TRD

        Exclusion Criteria:

          -  Other comorbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susan Stansfield, PhD</last_name>
    <phone>+44-7780-523013</phone>
    <email>sue@compasspathways.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kadima Neuropsychiatry Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Johnson</last_name>
      <email>olgaJ@kadimanp.com</email>
    </contact>
    <investigator>
      <last_name>David Feifel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altman Clinical and Translational Research Institute, University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Cardoso</last_name>
      <email>mailto:PsilocybinStudy@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Sidney Zisook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Department of Psychiatry</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Hawkins</last_name>
      <email>jhawk@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Charles DeBattista</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mood and Anxiety Disorders Program Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Mletzk</last_name>
      <email>tmletzk@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Boadie Dunlop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ray Worthy Psychiatry LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Sheppard Pratt Health System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsie J Kaier</last_name>
      <email>KKaier@sheppardpratt.org</email>
    </contact>
    <investigator>
      <last_name>Scott Aaronson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mia Silvan-Grau</last_name>
      <email>mia.silvan-grau@nyspi.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>David Hellerstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Center of Excellence on Mood Disorders, University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeria Cuellar</last_name>
      <email>Valeria.A.Cuellar@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jair Soares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canadian Rapid Treatment Centre of Excellence</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Cullen</last_name>
      <email>Clare.Cullen@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Ishrat Hussain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Mental Health Czech Republic</name>
      <address>
        <city>Klecany</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zusana Postranecka</last_name>
      <email>Zuzana.Postranecka@nudz.cz</email>
    </contact>
    <contact_backup>
      <last_name>Alice Heuschneiderova</last_name>
    </contact_backup>
    <investigator>
      <last_name>Tomas Palenicek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Enhed for Psykiatrisk Forskning, Psykiatrien i Aalborg</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Gulbæk</last_name>
      <email>m.gulbaek@rn.dk</email>
    </contact>
    <investigator>
      <last_name>Rasmus Licht</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tallaght University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Baker</last_name>
      <email>abaker@clinicalresearchplatform.com</email>
    </contact>
    <investigator>
      <last_name>Veronica O'Keane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groningen University Medical Centre</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurice Vischjager</last_name>
      <email>m.vischjager@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Robert Schoevers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence van der Does</last_name>
      <email>F.H.S.van_der_Does@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Nic van der Wee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Utrecht University Medical Centre</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Ywema</last_name>
      <email>P.C.Ywema@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Metten Somers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unidade de Neuropsiquiatria, Centro Clinico Champalimaud</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliveira Maia</last_name>
    </contact>
    <investigator>
      <last_name>Albino Oliveira Maia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Dia Numancia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Borras</last_name>
      <email>s.borras@pssjd.org</email>
    </contact>
    <investigator>
      <last_name>Oscar Alvarez Bobo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Hospital del Mar of Medical Research (IMIM)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matilde Elices</last_name>
      <email>melices@imim.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research and Imaging Centre</name>
      <address>
        <city>Bristol</city>
        <state>Avon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monalisa Bora</last_name>
      <email>monalisa.bora@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Tim Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wolfson Research Centre, Campus for Ageing and Vitality</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Massey</last_name>
      <email>Anna.Massey@ntw.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Hamish McAllister-Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College London, Institute of Psychiatry, Psychology and Neurology</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Bird</last_name>
      <email>catherine.bird@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Allan Young</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greater Manchester Mental Health Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2018</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psilocybin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

